AR063603A1 - Usos de variantes de un activador de plasminogeno de tejidos - Google Patents

Usos de variantes de un activador de plasminogeno de tejidos

Info

Publication number
AR063603A1
AR063603A1 ARP070104960A ARP070104960A AR063603A1 AR 063603 A1 AR063603 A1 AR 063603A1 AR P070104960 A ARP070104960 A AR P070104960A AR P070104960 A ARP070104960 A AR P070104960A AR 063603 A1 AR063603 A1 AR 063603A1
Authority
AR
Argentina
Prior art keywords
catheter
tenecteplase
instructions
variants
bfr
Prior art date
Application number
ARP070104960A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR063603A1 publication Critical patent/AR063603A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/285—Catheters therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M2025/0019—Cleaning catheters or the like, e.g. for reuse of the device, for avoiding replacement

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ARP070104960A 2006-11-07 2007-11-07 Usos de variantes de un activador de plasminogeno de tejidos AR063603A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86475806P 2006-11-07 2006-11-07
US98348907P 2007-10-29 2007-10-29

Publications (1)

Publication Number Publication Date
AR063603A1 true AR063603A1 (es) 2009-02-04

Family

ID=39362326

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104960A AR063603A1 (es) 2006-11-07 2007-11-07 Usos de variantes de un activador de plasminogeno de tejidos

Country Status (10)

Country Link
US (1) US8916148B2 (cg-RX-API-DMAC7.html)
EP (1) EP2086571A2 (cg-RX-API-DMAC7.html)
JP (1) JP5871449B2 (cg-RX-API-DMAC7.html)
AR (1) AR063603A1 (cg-RX-API-DMAC7.html)
CA (1) CA2668347C (cg-RX-API-DMAC7.html)
CL (1) CL2007003211A1 (cg-RX-API-DMAC7.html)
PE (2) PE20120639A1 (cg-RX-API-DMAC7.html)
TW (1) TW200826981A (cg-RX-API-DMAC7.html)
UY (1) UY30693A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008070353A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100102745A (ko) 2001-11-26 2010-09-24 제넨테크, 인크. 카테터 조성물 및 그의 용도
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses
CN103391785A (zh) * 2010-12-23 2013-11-13 热诺瓦生物制药有限公司 替萘普酶的药用组合物
GB201415062D0 (en) * 2014-08-26 2014-10-08 Aplagon Oy Therapeutic
DK3209767T3 (da) * 2014-10-21 2020-11-02 Gennova Biopharmaceuticals Ltd Hidtil ukendt oprensningsfremgangsmåde til isolering og kommerciel fremstilling af rekombinant tnk-tpa (tenecteplase)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484A7 (fi) 1982-05-05 1983-11-06 Genentech Inc Ihmiskudoksen plasminogeenien aktivaattori.
US5000185A (en) 1986-02-28 1991-03-19 Cardiovascular Imaging Systems, Inc. Method for intravascular two-dimensional ultrasonography and recanalization
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
US5270198A (en) 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8820945D0 (en) 1988-09-07 1988-10-05 Smith & Nephew Medical articles
NZ230808A (en) 1988-10-24 1993-04-28 Squibb & Sons Inc Pharmaceutical compositions and combinations containing an angiotensin-converting enzyme inhibitor and a thrombolytic agent
AU7998091A (en) 1990-05-17 1991-12-10 Harbor Medical Devices, Inc. Medical device polymer
US5399158A (en) 1990-05-31 1995-03-21 The United States Of America As Represented By The Secretary Of The Army Method of lysing thrombi
US5363754A (en) 1991-09-03 1994-11-15 Grainco Queensland Co-Operative Association Limited Apparatus for preparing animal feedstuff from cotton seed
NZ253556A (en) 1992-06-03 1995-11-27 Genentech Inc Tissue plasminogen activator (t-pa) variants (with extended circulatory half-life and/or potency); preparation, compositions, host cells, dna sequences, and expression vehicles thereof
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5362754A (en) 1992-11-12 1994-11-08 Univ. Of Tx Md Anderson Cancer Center M-EDTA pharmaceutical preparations and uses thereof
NZ276633A (en) 1993-11-24 1998-04-27 Du Pont Merck Pharma Isoxazole and isoxazoline derivatives and pharmaceutical compositions thereof
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5885967A (en) 1994-03-04 1999-03-23 Eli Lilly And Company Antithrombotic agents
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US5556380A (en) 1995-04-05 1996-09-17 Duke University Method for removing fibrin sheaths from catheters
US5772640A (en) 1996-01-05 1998-06-30 The Trustees Of Columbia University Of The City Of New York Triclosan-containing medical devices
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5932299A (en) 1996-04-23 1999-08-03 Katoot; Mohammad W. Method for modifying the surface of an object
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5837688A (en) 1996-11-27 1998-11-17 Gelfand; Mathew I. Use of thrombolytic reagents for prevention of vascular disease
GB9626795D0 (en) 1996-12-23 1997-02-12 Geistlich Soehne Ag Combating infection in delivery systems
AU5526098A (en) 1996-12-23 1998-07-17 Biochem Pharma Inc. Bicyclic thrombin inhibitors
US5981826A (en) 1997-05-05 1999-11-09 Georgia Tech Research Corporation Poly(vinyl alcohol) cryogel
JPH10328293A (ja) 1997-06-04 1998-12-15 Unitika Ltd 医療用具及びその製造方法
US6206914B1 (en) 1998-04-30 2001-03-27 Medtronic, Inc. Implantable system with drug-eluting cells for on-demand local drug delivery
US6166007A (en) 1998-07-02 2000-12-26 Sodemann; Klaus Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
US6174537B1 (en) 1998-09-25 2001-01-16 Becton, Dickinson And Company Catheter flush solution and method for its use
WO2000053264A1 (en) 1999-03-11 2000-09-14 Du Pont Pharmaceuticals Company Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
BR0010380A (pt) 1999-03-11 2002-03-26 Du Pont Pharm Co Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
CA2302720C (en) 1999-03-29 2009-07-14 Ed Geistlich Sohne Ag Fur Chemische Industrie Anticoagulant/sterilizing compositions and methods
US6187768B1 (en) 1999-06-01 2001-02-13 Becton, Dickinson And Company Kit for flushing medical devices and method of preparation
EP1060747A3 (en) 1999-06-16 2001-12-05 New York Blood Center, Inc. Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
US6592564B2 (en) 1999-07-23 2003-07-15 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6350251B1 (en) 2000-01-18 2002-02-26 Biolink Corporation Biocidal locks
US20010031981A1 (en) 2000-03-31 2001-10-18 Evans Michael A. Method and device for locating guidewire and treating chronic total occlusions
ATE394134T1 (de) 2000-05-10 2008-05-15 Ash Access Technology Inc Kathetersperrlösung mit photo-oxidant
WO2002017714A2 (en) 2000-08-25 2002-03-07 Organ Recovery Systems, Inc. Methods of thrombolytic organ treatment and repair
US20050215978A1 (en) * 2001-05-25 2005-09-29 Ash Stephen R Method of enhancing catheter patency using a citrate salt catheter lock solution
KR20100102745A (ko) * 2001-11-26 2010-09-24 제넨테크, 인크. 카테터 조성물 및 그의 용도
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
EP1442753B1 (en) * 2003-02-03 2007-02-21 Polaschegg, Hans-Dietrich, Dr.techn. Composition for the prevention of indwelling device related infection
US7696182B2 (en) * 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en) 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2668347C (en) 2006-11-07 2017-06-20 Genentech, Inc. Tissue plasminogen activator variant uses

Also Published As

Publication number Publication date
EP2086571A2 (en) 2009-08-12
JP5871449B2 (ja) 2016-03-01
CA2668347C (en) 2017-06-20
TW200826981A (en) 2008-07-01
US20120270299A1 (en) 2012-10-25
PE20081488A1 (es) 2008-10-30
JP2010509229A (ja) 2010-03-25
CL2007003211A1 (es) 2008-05-30
PE20120639A1 (es) 2012-05-26
CA2668347A1 (en) 2008-06-12
WO2008070353A3 (en) 2008-08-28
US8916148B2 (en) 2014-12-23
UY30693A1 (es) 2008-05-02
WO2008070353A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR063603A1 (es) Usos de variantes de un activador de plasminogeno de tejidos
ECSP088866A (es) Uso de inhibidores de dpp iv
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
CO6382132A2 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
BR112015005351A2 (pt) sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
BR112015003836A2 (pt) sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
CO6592015A2 (es) Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal
CO6640324A2 (es) Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
MX2015008529A (es) Solucion para conservar conductos vasculares.
MX2009011900A (es) Curacion de herida diabetica.
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
EA200971073A1 (ru) Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
MX2016006651A (es) Soluciones para incrementar la estabilidad y la vida util de una solucion de conservacion de organos y tejidos.
DK1673074T3 (da) Flydende præparat, indeholdende tobramycin
AR066670A1 (es) Concentrado de esmolol
ATE400257T1 (de) Stabile pharmazeutische zusammensetzung mit linezolid form iv
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal